Evidence map›Paper›PMID 31748959›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Dual-targeted therapeutic strategy combining CSC-DC-based vaccine and cisplatin overcomes chemo-resistance in experimental mice model.

N E El-Ashmawy, M L Salem, E G Khedr, E A El-Zamarany, A O Ibrahim

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. CD24: A Novel Target for Cancer Immunotherapy.Journal of personalized medicine · 2022
    Review
  10. Review
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

N E El-AshmawyBiochemistry Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
M L SalemZoology Department, Faculty of Science, Tanta University, Tanta, Egypt.
E G KhedrBiochemistry Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
E A El-ZamaranyClinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
A O IbrahimBiochemistry Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt. amera.ibrahim@pharm.tanta.edu.eg.ORCID http://orcid.org/0000-0002-8669-4466
Tanta University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeEmerging evidence suggests that one of the main reasons of chemotherapy treatment failure is the development of multi-drug resistance (MDR) associated with cancer stem cells (CSCs). Our aim is to identify a therapeutic strategy based on MDR-reversing agents. MATERIALS AND

methodsCSC-enriched Ehrlich carcinoma (EC) cell cultures were prepared by drug-resistant selection method using different concentrations of cisplatin (CIS). Cell cultures following drug exposure were analyzed by flow cytometry for CSC surface markers CD44 RESULTS AND

conclusionCo-treatment with CSC-DC and CIS resulted in a significant tumor growth inhibition. Furthermore, the greatest response of downregulation of MDR and Bcl-2 relative gene expression were achieved in the same group. In parallel, the histopathological observations demonstrated enhanced apoptosis and absence of mitotic figures in tumor tissues of the co-treatment group. Dual targeting of resistant cancer cells using CSC-DC vaccine along with cisplatin represents a promising therapeutic strategy that could suppress tumor growth, circumvent MDR, and increase the efficacy of conventional chemotherapies.

Indexed as

Drug Resistance, NeoplasmAnimalsAntineoplastic AgentsApoptosisCancer VaccinesCarcinoma, Ehrlich TumorCisplatinDendritic CellsMiceNeoplastic Stem CellsProto-Oncogene Proteins c-bcl-2Antineoplastic AgentsBcl2 protein, mouseCancer VaccinesCisplatinProto-Oncogene Proteins c-bcl-2Bcl-2Cancer stem cellsCisplatinDendritic cellsImmunotherapyMulti-drug resistance

Identifiers

PMID31748959
OpenAlexW2990627732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.